NeuBase Therapeutics (STU:O7P) Accounts Payable & Accrued Expense : €0.59 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Accounts Payable & Accrued Expense?

NeuBase Therapeutics's quarterly accounts payable & accrued expense declined from Mar. 2023 (€0.87 Mil) to Jun. 2023 (€0.73 Mil) and declined from Jun. 2023 (€0.73 Mil) to Sep. 2023 (€0.59 Mil).

NeuBase Therapeutics's annual accounts payable & accrued expense declined from Sep. 2019 (€1.68 Mil) to Sep. 2020 (€1.67 Mil) but then increased from Sep. 2020 (€1.67 Mil) to Sep. 2021 (€2.27 Mil).

NeuBase Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for NeuBase Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Accounts Payable & Accrued Expense Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4.05

0.04

1.68

1.67

2.27

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.76	1.35	0.87	0.73	0.59

NeuBase Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines